Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to -$9.4 billion.

  • Astrazeneca's Operating Expenses rose 726.68% to -$9.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$34.2 billion, marking a year-over-year decrease of 180.27%. This contributed to the annual value of -$34.2 billion for FY2025, which is 180.27% down from last year.
  • Latest data reveals that Astrazeneca reported Operating Expenses of -$9.4 billion as of Q4 2025, which was up 726.68% from -$8.7 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Operating Expenses ranged from a high of -$3.2 billion in Q1 2021 and a low of -$10.1 billion during Q4 2024
  • Its 5-year average for Operating Expenses is -$7.5 billion, with a median of -$7.7 billion in 2023.
  • In the last 5 years, Astrazeneca's Operating Expenses soared by 2135.38% in 2021 and then crashed by 11975.23% in 2022.
  • Over the past 5 years, Astrazeneca's Operating Expenses (Quarter) stood at -$7.7 billion in 2021, then grew by 5.91% to -$7.2 billion in 2022, then decreased by 16.53% to -$8.4 billion in 2023, then fell by 19.46% to -$10.1 billion in 2024, then rose by 7.27% to -$9.4 billion in 2025.
  • Its last three reported values are -$9.4 billion in Q4 2025, -$8.7 billion for Q3 2025, and -$8.4 billion during Q2 2025.